 Connection
David Moreno to Middle Aged
This is a "connection" page, showing publications David Moreno has written about Middle Aged.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.200 |
|
|
|
-
Moreno DF, Nadeu F, Brasó-Maristany F, Vaqué S, Paz S, Mañé J, Cardús O, Medina E, Lozano E, Rodríguez-Lobato LG, de Daniel A, Tovar N, Cibeira MT, Bladé J, Rosiñol L, Prat A, Colomer D, Fernández de Larrea C. Genomic and immune profiling of prognostic risk groups in IgM gammopathy reveals novel biomarkers beyond MYD88 L265P. Front Immunol. 2025; 16:1604089.
Score: 0.052
-
Moreno DF, Oriol A, de la Rubia J, Hernández MT, Iñigo MB, Palomera L, de Arriba F, González Y, Teruel AI, Pardo JL, López de la Guía A, Sampol A, Ríos-Tamayo R, Sureda A, Gutiérrez NC, Calasanz MJ, Ramos MLM, Mateos MV, San Miguel J, Lahuerta JJ, Bladé J, Rosiñol L. Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials. Clin Lymphoma Myeloma Leuk. 2025 Jul; 25(7):494-504.
Score: 0.050
-
Rodríguez-Lobato LG, de Daniel A, Pereira A, Fernández de Larrea C, Tovar N, Cibeira MT, Moreno DF, Mateos JM, Llobet N, Carcelero E, Munárriz D, Bladé J, Rosiñol L. Attrition rates and treatment outcomes in multiple myeloma: real-world data over a 40-year period. Blood Cancer J. 2025 May 26; 15(1):103.
Score: 0.013
-
Moreno D, Ferrándiz L, Pérez-Bernal AM, Ríos JJ, Carrasco R, Camacho F. [Evaluation of a screening system for patients with pigmented lesions using store-and-forward teleconsultation]. Actas Dermosifiliogr. 2005 May; 96(4):222-30.
Score: 0.013
-
Zugasti I, Tormo-Ratera M, Oliver-Caldés A, Soler-Perromat JC, González-Calle V, Moreno DF, Cabañas V, López-Muñoz N, Bartolomé-Solanas Á, Español-Rego M, Reguera-Ortega JL, Rosiñol L, López-Corral L, Tovar N, Rodríguez-Lobato LG, Alvarez Perez RM, Varea S, Olesti E, Gomez-Grande A, Frutos L, Tamayo P, Juan M, Moraleda JM, Urbano-Ispizua Á, González-Navarro EA, Martínez-López J, Mateos MV, Tomás X, Setoain X, Fernández de Larrea C. Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma. Blood Adv. 2025 Feb 11; 9(3):571-582.
Score: 0.013
-
Oliver-Caldes A, Español-Rego M, Zabaleta A, González-Calle V, Navarro-Velázquez S, Inogés S, de Cerio AL, Cabañas V, López-Muñoz N, Rodríguez-Otero P, Reguera JL, Moreno DF, Martínez-Cibrian N, López-Corral L, Pérez-Amill L, Martin-Antonio B, Rosiñol L, Cid J, Tovar N, Sáez-Peñataro J, López-Parra M, Olesti E, Guillén E, Varea S, Rodríguez-Lobato LG, Battram AM, González MS, Sánchez-Salinas A, González-Navarro A, Ortiz-Maldonado V, Delgado J, Prósper F, Juan M, Martínez-López J, Moraleda JM, Mateos MV, Urbano-Ispizua Á, Paiva B, Pascal M, Fernández de Larrea C. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma. Clin Cancer Res. 2024 May 15; 30(10):2085-2096.
Score: 0.012
-
Oliver-Caldes A, Jiménez R, Español-Rego M, Cibeira MT, Ortiz-Maldonado V, Quintana LF, Castillo P, Guijarro F, Tovar N, Montoro M, Benitez-Ribas D, Bataller A, González-Navarro EA, Cid J, Lozano M, Perez-Amill L, Martin-Antonio B, Mena MP, Moreno DF, Rodríguez-Lobato LG, Campistol JM, Calvo G, Bladé J, Rosiñol L, Juan M, Pascal M, Urbano-Ispizua A, Fernández de Larrea C. First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma. J Immunother Cancer. 2021 12; 9(12).
Score: 0.010
-
Isola I, Brasó-Maristany F, Moreno DF, Mena MP, Oliver-Calders A, Paré L, Rodríguez-Lobato LG, Martin-Antonio B, Cibeira MT, Bladé J, Rosiñol L, Prat A, Lozano E, Fernández de Larrea C. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease. Front Immunol. 2021; 12:792609.
Score: 0.010
-
Rodríguez-Lobato LG, Pereira A, Fernández de Larrea C, Cibeira MT, Tovar N, Jiménez-Segura R, Moreno DF, Oliver-Caldés A, Rosiñol L, Bladé J. Real-world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45-year period. Br J Haematol. 2022 02; 196(3):649-659.
Score: 0.010
-
Isola I, Moreno DF, Moga E, Mena MP, Tovar N, Rodríguez-Lobato LG, Oliver-Caldés A, Salgado MC, Brasó-Maristany F, Yagüe J, Cibeira MT, Prat A, Rosiñol L, Bladé J, Fernández de Larrea C. Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease. Ann Hematol. 2021 Dec; 100(12):2997-3005.
Score: 0.010
-
Cid J, Carbassé G, Suárez-Lledó M, Moreno DF, Martínez C, Gutiérrez-García G, Fernández-Avilés F, Rosiñol L, Giavedoni P, Mascaró JM, Agustí C, Marín P, Rovira M, Urbano-Ispizua Á, Lozano M. Efficacy and safety of one-day offline extracorporeal photopheresis schedule processing one total blood volume for treating patients with graft-versus-host disease. Transfusion. 2019 08; 59(8):2636-2642.
Score: 0.008
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|